Business Context and Reporting Period
Company: Exelixis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Industry: Biotechnology (Oncology)
Primary Focus: The company has shifted its strategy to focus exclusively on the development and commercialization of cabozantinib (XL184), a small molecule inhibitor of MET, VEGFR2, and RET. All other non-partnered programs have been discontinued or are being pursued for external collaboration.
Key Financial Metrics
| Metric | 2010 | 2009 | 2008 |
|---|---|---|---|
| Total Revenues | $185.0 million | $151.8 million | $117.9 million |
| Net Loss (Attributable to Exelixis) | $(92.3) million | $(135.2) million | $(162.9) million |
| Research & Development Expenses | $210.7 million | $234.7 million | $257.4 million |
| General & Administrative Expenses | $33.0 million | $34.4 million | $36.9 million |
| Restructuring Charges | $32.7 million | $0 | $2.9 million |
| Cash & Cash Equivalents (End of Period) | $97.4 million | $86.8 million | $247.7 million |
| Total Investments & Cash | $256.4 million | $221.0 million | $284.2 million |
| Working Capital | $(16.5) million | $22.9 million | $82.0 million |
| Long-Term Debt | $170.7 million | $40.4 million | $97.3 million |
Note: The company reported a negative working capital position for the first time in the reported period due to restructuring liabilities and current debt obligations.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 22% to $185.0 million, driven primarily by collaboration agreements with sanofi-aventis and Bristol-Myers Squibb (BMS). BMS accounted for 50% of revenues, and sanofi-aventis for 42%.
- Restructuring: The company implemented two major restructuring plans in 2010 (March and December), resulting in a workforce reduction of approximately 399 employees (roughly 65% of the workforce over two years). This led to a one-time charge of $32.7 million.
- Debt Structure: Significant new debt was incurred in 2010, including a $124.0 million secured convertible note with Deerfield Management Company and an $80.0 million term loan from Silicon Valley Bank. Total debt increased from $79.6 million in 2009 to $208.5 million in 2010.
- Collaboration Shifts: In June 2010, BMS terminated its collaboration regarding cabozantinib, reverting full rights to Exelixis. Exelixis received a $17.0 million transition payment. Conversely, new collaborations were signed with BMS for TGR5 and ROR programs in late 2010.
- Net Loss Improvement: Despite the restructuring charge, the net loss attributable to Exelixis decreased by approximately 32% compared to 2009, primarily due to increased revenues and reduced operating expenses from headcount reductions.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cabozantinib Development: The company expects to release top-line results from the Phase 3 trial for medullary thyroid cancer in the first half of 2011 and potentially submit a New Drug Application (NDA) in the second half of 2011.
- Liquidity: Management anticipates that current cash, investments, and expected collaboration funding will sustain operations for at least 12 months following the filing date (February 2011).
- Cost Management: The company expects to incur additional restructuring charges of $25 million to $30 million in 2011 related to facility exits and termination benefits.
Key Risks and Contingencies
- Capital Requirements: The company has a history of net losses and expects to continue incurring losses. It may need to raise additional capital to fund cabozantinib development and repay debt obligations.
- Debt Covenants: The company is subject to strict financial covenants with GlaxoSmithKline, Deerfield, and Silicon Valley Bank regarding working capital and cash balances. Failure to comply could trigger acceleration of debt.
- Debt Repayment: A final installment of $35.9 million on the GlaxoSmithKline loan is due in October 2011. Repayment may be made in cash or stock, potentially causing dilution.
- Regulatory Approval: Commercial success is entirely dependent on the regulatory approval and market acceptance of cabozantinib, which faces significant clinical and regulatory risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $256.4 million in total liquid assets against the projected cash burn rate, considering the upcoming $35.9 million GSK loan payment due in October 2011.
- Debt Covenants: Confirm compliance with the specific working capital and cash balance covenants required by the GSK, Deerfield, and Silicon Valley Bank agreements.
- Cabozantinib Phase 3 Data: Monitor the release of top-line results for the medullary thyroid cancer trial expected in H1 2011, as this is the primary catalyst for future valuation.
- Restructuring Costs: Track the actual realization of the projected $25-$30 million in additional restructuring charges for 2011 and the timeline for facility subleases.
- Collaboration Milestones: Review the status of funded programs with partners (sanofi-aventis, BMS, Boehringer Ingelheim) to ensure continued revenue streams from research funding and milestones.